Calcineurin inhibitors: 40 years later, can’t live without
The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.
Abstract
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcineurin inhibitors, including ciclosporin and tacrolimus, inhibit T cell proliferation and activation through targeting IL-2 (58).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [58]
In the citing paper
“Ciclosporin and tacrolimus are immunosuppressants that inhibit calcineurin, a key signaling phosphatase, by binding to their respective immunophilins - cyclophilin and FKBP12 (76).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
In the citing paper
“A major downstream effect is suppression of interleukin (IL)-2 transcription, thereby inhibiting T cells differentiation, survival, and subsequent antibody production and CTL activities via effector TH cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
Citations
Cites
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325 · cited 2×
“Regulatory T cells have been shown to be essential for immune tolerance induction in transplantation (16).”
BackgroundTRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603 · cited 1×
“scriptional activation of genes encoding cytokines, including IL-2 and IL-4, and CD40 ligand (12).”
BackgroundThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Creighton, T. E. (1992) · Cited by 1,583
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509 · cited 1×
“Many mechanisms were suggested, including an imbalance between vasoconstrictive and vasodilatory mediators (46), an activation of the renin-angiotensin-aldosterone system (47), an increase in the release of endothelin (5), an increase in free radicals (48), and a sympathetic nerve activation in the native kidneys thro…”
BackgroundPirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Calne, R. Y., Rolles, K., Thiru, S., Mcmaster, P., Craddock, G. N., Aziz, S., White, D. J. G., Evans, D. B., Dunn, D. C., Henderson, R. G., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92440-1 · Cited by 1,083
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002 · cited 1×
“The nephrotoxicity of cyclosporine, reported by Calne and colleagues in the early human studies, remains a major concern for the medical community today (21).”
BackgroundVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957 · cited 2×
“The cardiovascular and metabolic profiles were better in belatacept groups compared with patients receiving cyclosporine (70).”
Background
Research works printed but not linked: 1
- Klee, 1988, Calcineurin, Adv. Enzymol. Relat. Areas Mol. Biol., 61, 149
Cited by
Items 301–337 of 337
Smets, F. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00018-5
Bálint, A. (2015) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.2516
Post-liver transplant HBV infection (Review)
Nikogosova, A. D., Umrik, D. V., & Tsirulniкova, O. M. (2022) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2022-2-31-38
Emerging Peptide Drug Modalities for Intracellular Target Space
Sawyer, T. K. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-04544-8_8
Wojciuk, B., Bogucka, A. E., Czaplewska, P., Okulewicz, P., Wojciechowska‐Koszko, I., Ciechanowski, K., & Kabat‐Koperska, J. (2022) · Clinical and Translational Science · doi:10.1111/cts.13432
El-Reshaid, K., & Al-Bader, S. (2023) · Open Journal of Nephrology · doi:10.4236/ojneph.2023.131001
Uysal, C., oğuz, H., Burgucu, B. B., Denız, K., & Kocyigit, I. D. (2023) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.1211440
Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis
Atluri, K., Manne, S., Nalamothu, V., Mantel, A., Sharma, P. K., & Babu, R. J. (2023) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2023042979
Kumar, D., Gulzar, K., Alalawi, F. J. A., Seddik, A. A., Alnour, H. H., Ahmed, M., Najad, S., Yousif, H., Railey, M., & Alhadari, A. K. (2023) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000531665
Post‐Transplant Phase: From ICU Discharge to Hospital Discharge
Shtraichman, O., & Kramer, M. R. (2023) · Wiley eBooks · doi:10.1002/9781119633884.ch90
Mycophenolate Mofetil for the Long-Term Treatment of Htlv-1 Associated MyelopathyPreprint
Sanz, M., Chernet, S., Shymansky, J., Mandel, A., Chitrakar, A., Kaminski, H. J., Ghosh, P., & Soriano-Sarabia, N. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4661217
Examining the association of immunosuppressants and wound healing: a narrative review
Appoo, A., Christensen, B. L., & Somayaji, R. (2023) · WCET Journal · doi:10.33235/wcet.43.4.32-39
“8 Therefore, CNI’s disable one of the main arms of the body’s adaptive immune response.”
BackgroundAllograft persistence: The next frontier for allogeneic γδ T cell therapy
Fowler, D. W., & Fisher, J. P. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21766-1.00001-1
Calcineurin inhibitors promote chronic alloimmunity via propagation of central memory T cell subsets
Bermea, R. S., & Gardner, J. M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.11.020
Khim, S. (2025) · International Journal of Clinical Medical Research · doi:10.61466/ijcmr3020003
“17 It is a calcineurin inhibitor that regulates T cell activity, which in turn supports antibody-producing B cells 18 It may also enhance T regulatory cells.”
Choy, J. C., & Stojcic, M. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00037-6
Mulder, M. B., Busschbach, J. J. V., van Hoek, B., Polak, W. G., Alwayn, I. P. J., de Winter, B. C. M., Murad, S. D., Verhey‐Hart, E., Elshove, L., Erler, N. S., et al. (2025) · Transplant International · doi:10.3389/ti.2025.14189
“CNIs are associated with neurotoxicity and affect the central and peripheral nervous systems [5, 6].”
Cancer Risk in the Adult Solid Organ Transplant Recipient
Wong, C. J., & Blosser, C. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-98076-3_10
Differential regulation of TCR-induced ZFP36 and ZFP36L1 expression by cyclosporin A in CD8+ T cellsPreprint
Evans, M. J., Mitchell, T. J., Zaucha, M., Petkau, G., & Turner, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678222
Shi, Y., Lou, Z., Zhang, Z., Xiao, L., Wang, Y., & Gao, Y. (2025) · Nano Research · doi:10.26599/nr.2025.94908192
Immune Modulating and Immunosuppressive Drugs
Attarha, B. O., Sharma, R., Majmudar, V. H., Shapiro, L. S., Flint, A., & Ghali, P. (2025) · Clinical gastroenterology · doi:10.1007/978-3-032-07868-1_20
Zhou, S. Y., Rajanayake, K. K., He, M., Wen, B., Lkhagva, A., Yap, E., Sun, D., Cross, J. L., Engelke, K. J., & Huizinga, R. B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-025-03943-y
“First-generation CNIs such as cyclosporine A (CSA) and tacrolimus (TAC) have been used in immunosuppression regimens for solid organ transplantation for decades, with efficacy subsequently demonstrated in the treatment of multiple autoimmune diseases [5, 6].”
Invariant Natural Killer T Cells in Solid Organ Transplantation
Cheng, H., Yu, Y., & Luo, X. (2026) · Current Transplantation Reports · doi:10.1007/s40472-026-00505-y
“Such an inhibition leads to reduced IL-2, IL-4, and CD40L expressions, which ultimately prevents the activation of T cells [ 84 , 85 ].”
Matsumoto, Y., Shimizu, Y., Nakayama, M., Takizawa, M., Kurakado, S., & Sugita, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344259 · Cited by 1
Burke, O. M., Rivera, F. C., Jaller, J. A., & Tang, J. C. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.03.078
Réponses lymphocytaires T dans le contexte des infections par le virus de l'hépatite E
Barragué, H. (2018) · theses.fr (ABES) · doi:10.70675/76b4d5f8z476dz40a4za78cz2fdd2cac67ff
Nemes, B., Szeredi, Á., Abonyi‐Tóth, Z., Balogh, O., Dimovics, A., Fazekas, D., & Szederkényi, E. (2026) · Transplantology · doi:10.3390/transplantology7020010
Nolze, A., & Großmann, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819168
“Several exogenous calcineurin inhibitors exist that are used as immunosuppressant (Azzi et al., 2013).”
Juri, J. M. R., VANIN, A., Castro-Villegas, F., Zapata-Palomino, M., Zúñiga-Gaitán, I. A., Charfuelan-Caicedo, J. D., & Téllez-Fina, C. (2026) · Revista Colombiana de Cirugía · doi:10.30944/20117582.3074
Zhou, H., Zhou, G., Xiang, W., Ren, G., Dou, X., Chen, J., Tang, X., Zhang, H., Wang, X., Xiaohua, L., et al. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02176-6
“Calcineurin inhibitors (CNIs), including Cyclosporine A (CsA) and Tacrolimus (FK506), are widely used immuno-suppressive agents in allo-HSCT, primarily preventing graft rejection by inhibiting T-cell activation [ 6, 7].”
Treatment of Myasthenia Gravis
Kaminski, H. J. (2026) · Current clinical neurology · doi:10.1007/978-3-032-19140-3_11
BABIN, P., Boulay, H., Lethimonier, C., Toupin, M., Prieto, F. J. F., Lesné, L., Lavoué, V., Vigneau, C. M., & Mazaud‐Guittot, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10280476/v1
Hyodeoxycholic acid ameliorates tacrolimus-induced diabetes by modulating the FXR-FGF15 axis
Hu, N., Qian, M., Liu, Y., Jiang, Z., Xu, C., Zhang, W., & Jiang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1865237
Planning Intermittent CalciNeurin Inhibitor Controls—The piCNIc Retrospective Cohort Study
Bellissimo, V., Tran, L., Bernard‐Tessier, G., Denault, J.-S., Pelletier, S., Statie, A., Letarte, N., Huard, G., Morisset, J., & Ferreira, V. (2026) · Clinical Transplantation · doi:10.1111/ctr.70633
“TDM also helps minimize adverse effects associated with CNIs, such as nephrotoxicity—one of the most common and feared complications following SOT [ 5, 6 ].”
InfluentialStimuli-responsive polymer carrier delivery of natural products for inflammation treatment: A review
Wang, C., Kang, X., Tang, Y., Wang, Y., Chen, Z., You, Y., Huang, W., & Zhan, J. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101789
BindingDB (2022) · UC San Diego · doi:10.7270/q2h135tk
Metadata
- Authors
- Azzi, J. R., Sayegh, M. H., & Mallat, S. G.
- Affiliations
- Brigham and Women's Hospital (US)
- American University of Beirut (LB)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12
- Volume
- 191
- Issue
- 12
- Pages
- 5785-5791
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1592567691
- Cited by
- 337
- References
- 90
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 26 · 2023: 32 · 2022: 44 · 2021: 38 · 2020: 27 · 2019: 27 · 2018: 25 · 2017: 17 · 2016: 25 · 2015: 14 · 2014: 12
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- calcineurin inhibitors, cyclosporine, tacrolimus, organ transplantation, immunosuppression, nephrotoxicity, drug toxicity reduction, autoimmune disease therapy, mechanism of action
- MeSH terms
- Animals, Autoimmune Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Therapy, Combination, Forecasting, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Diseases, Lymphocyte Activation, T-Lymphocytes, Meta-Analysis as Topic, Multicenter Studies as Topic, Kidney Transplantation, Randomized Controlled Trials as Topic, Tacrolimus, Cyclosporine, Calcineurin, History, 20th Century, History, 21st Century, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.